ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026
Molecular subtypes and survival patterns of endometrial cancer in a South Indian cohort.
Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveThis study investigates outcomes of The Cancer Genome Atlas (TCGA)-surrogate molecular types of endometrial cancer in South Indian patients, including polymerase epsilon (POLE)-mutated, mismatch repair-deficient (MMRd), p53 aberrant, and no specific molecular profile (NSMP) types.
methodsThe retrospective cohort, followed-up prospectively consisted of 151 patients from two institutions in Kerala, India: Government Medical College, Kozhikode, and MVR Cancer Center. The study spanned from January 1, 2016, to October 31, 2024. Sanger sequencing of the POLE gene (exons 9 and 13), TP53 (exons 5-8), CTNNB1, and PTEN genes, along with immunohistochemistry for mismatch repair (MMR) proteins, p53, estrogen receptor, and progesterone receptor, was performed to determine molecular types and associated variables.
resultsThe study identified four subtypes: 39 POLE mutated (25.8%), 44 MMRd (29.1%), 29 p53 aberrant (19.2%), and 39 NSMP (25.8%). The 5-year recurrence-free survival (RFS) rates are POLE mutated (69%), MMRd (87%), p53abn (89%), and NSMP (64%) (P = 0.012). The study identified a "non-pathogenic" POLE-mutated subtype showing poor outcomes for overall survival (OS), disease-specific survival (DSS) and recurrence-free survival (RFS) (hazard ratios [HRs] for OS 5.45, P = 0.010; HR for DSS 4.83, P = 0.020; HR for RFS 4.12, P = 0.017) in multivariable analysis. Follow-up averaged 5.1 years. Estrogen receptor-positive low-grade endometrioid POLE-mutated tumors demonstrated excellent survival, while high-grade tumors negatively affected the POLE-mutated group. MMRd subtype, despite presenting in advanced stages with high-risk uterine factors, had excellent prognosis. The p53 aberrant group, predominantly with endometrioid histology and low-grade tumors, also showed good prognosis with standard treatment protocols. NSMP subtype revealed unfavorable outcome. Neither CTNNB1 mutation or ER PR status was noted to be a determinant of the poor outcome. Multiple-classifier tumors (>1 TCGA-surrogate type) were identified, with POLEmut-p53 being the largest group, showing characteristics similar to POLEmut.
conclusionThe study's findings diverge from prognostic implications of TCGA-surrogate molecular types, suggesting genetic diversity and ethnicity as potential outcome determinants in South Indian endometrial cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.